| |
 Dr. Michael Hayden
University of British Columbia, Centre for Molecular Medicine and Therapeutics
890 West 28th Ave.
Vancouver, BC
V5Z 4H4
Genome BC Project Leader
Michael Hayden is a full professor of Medical Genetics at the University of British Columbia and the Director of the Center for Molecular Medicine and Therapeutics in Vancouver. Dr. Hayden has served as Chief Scientific Officer for Xenon Pharmaceuticals Inc. since March 1999 and been a member of the Board since November 1996.
Author of over 400 peer-reviewed publications and 150 invited submissions, Dr. Hayden focuses his research primarily on genetic diseases. Dr. Hayden played a key role in the development of predictive testing for Huntington's disease (HD) and his research group was instrumental in the demonstration of proteolytic cleavage of Huntingtin, contributing to the understanding of HD pathogenesis.
The recipient of numerous prestigious honors and awards, Dr. Hayden was elected to the American Society of Clinical Investigation in 1992, the Board of the American Society of Human Genetics in 1994 and the Royal Society of Canada in 1995. Among his most recent awards are the 2003 Henry Friesen Award of the Royal College of Physicians and Surgeons of Canada, the 2001 Award of Excellence of the Genetics Society of Canada and the Ottawa Life Sciences Award of Merit. He also received the 1998 Distinguished Scientist Award of the Canadian Society of Clinical Investigation and the 2000 BC Biotechnology Alliance Award for Vision and Leadership,.
Dr. Hayden received his medical training (1975) and his PhD in Genetics (1979) from the University of Cape Town. He completed a post-doctoral fellowship and further training in Internal Medicine at Harvard Medical School.
« Back to Researcher Profiles
|
|
